Skip to main content
hero image

Cosentyx address hallmarks of disease icon

Here with you to help get the treatment response you need

In JUNIPERA in biologic-naive patients 

Reduction in disease activity in children with ERA9
JADAS-27 Change from Baseline Through Year 2 in ERA
  • Decrease in ERA disease activity with JADAS-27 improvement seen starting at Week 19

  • Most disease activity reduction occurred during the initial 4 weeks of COSENTYX treatment, with improvements observed until the end of Treatment Periods 1 and 29

In JUNIPERA, change from baseline in JADAS score for all patients and each JIA category through Week 12 (the end of open-label, single-arm Treatment Period 1) was a prespecified secondary end point. In Treatment Period 2, change from baseline in JADAS score was an exploratory end point. No clinical or statistical conclusions can be drawn.9

JADAS-27

JADAS, a composite disease activity score developed and validated for JIA, consists of 4 components9:

JADAS, a composite disease activity score developed and validated for JIA, consists of 4 components

JADAS-27 evaluates 27 joints, with scores ranging from 0 to 57. Higher scores indicate greater disease activity.9

*Measured on a 100-mm VAS.9

See disease activity reduction in JPsAr
A robust safety profile overallm
Convenient once-a-month maintenance dosing (every 4 weeks)m
*Limitations apply. Up to a $16,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. Limitations may apply in MA and CA. For complete Terms and Conditions details, call 1-844-267-3689.

Definitions

ACR, American College of Rheumatology; CRP, C-reactive protein; ERA, enthesitis-related arthritis; JADAS, juvenile arthritis disease activity score; JIA, juvenile idiopathic arthritis; JPsA, juvenile psoriatic arthritis; VAS, visual analog scale.

References

1. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.

2. Humira. Prescribing Information. AbbVie Inc; 2021.

3. Orencia. Prescribing Information. Bristol-Myers Squibb Co; 2021.

4. Actemra. Prescribing Information. Genentech Inc; 2022.

5. Ilaris. Prescribing Information. Novartis Pharmaceuticals Corp; 2020.

6. Simponi Aria. Prescribing Information. Janssen Biotech Inc; 2021.

7. Xeljanz. Prescribing Information. Pfizer Inc; 2022.

8. Taltz. Prescribing Information. Eli Lilly & Co; 2021.

9. Data on file. CAIN457F2304 Clinical Study Report. Novartis Pharmaceuticals Corp; June 2020.

a. Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582-590.

b. Data on file. CAIN457F2342 (FUTURE 5): 2-Year Interim Report. Novartis Pharmaceuticals Corp; May 2019.

c. Data on file. CAIN457F2342 (FUTURE 5): 2-Year Interim Report PASI 90 and ACR Components data. Novartis Pharmaceuticals Corp; January 2020.

d. Data on file. CAIN457F2342 (FUTURE 5): 2-Year Interim Report mNAPSI and PASI 100 data. Novartis Pharmaceuticals Corp; October 2019.

e. Data on file. CAIN457H2315 Data Analysis Report. Novartis Pharmaceuticals Corp; April 2020.

f. Data on file. CAIN457H2315 Clinical Study Report. Novartis Pharmaceuticals Corp; November 2019.

g. Data on file. CAIN457F2310 Data Analysis Report. Novartis Pharmaceuticals Corp; June 2019.

h. Data on file. CAIN457F2310 (MEASURE 2): Nocturnal Back Pain. Novartis Pharmaceuticals Corp; February 2021.

i. Data on file. CAIN457F2342 (FUTURE 5): Interim Data Analysis Report FACIT-Fatigue data through Week 52. Novartis Pharmaceuticals Corp; April 2019.

j. Poddubnyy DA, Rudwaleit M, Listing J, Braun J, Sieper J. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2010;69(7):1338-1341.

k. Data on file. CAIN457F2342 Clinical Study Report Interim Analysis-Week 24. Novartis Pharmaceuticals Corp; November 2017.

l. Data on file. CAIN457F2342 (FUTURE 5): 2-Year HAQ-DI biologic-naive data. Novartis Pharmaceuticals Corp; February 2021.

m. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.

n. Data on file. Selected EAIRs MEASURE 2 Year 5. Novartis Pharmaceuticals Corp; January 2020.

o. Nash P, Mease PJ, McInnes IB, et al; on behalf of the FUTURE 3 study group. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018;20(1):47.

p. Data on file. LTD Cosentyx Prescriber and Patient Counts. Novartis Pharmaceuticals Corp; July 2021.

q. Boonen A, Sieper J, van der Heijde D, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2015;44(5):556-562.

r. Data on file. CAIN457F2304 Clinical Study Report. Novartis Pharmaceuticals Corp; June 2020.

s. Data on file. CAIN457F2304 Data Analysis Report. Novartis Pharmaceuticals Corp; January 2022.

t. Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021;35(4):938-947.